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Abstract       
Background 
Kidney function reduces with age, increasing the risk of harm from increased blood levels of many 
medicines. Although estimated glomerular filtration rate (eGFR) is reported, for prescribing decisions 
ŝŶƚŚŽƐĞĂŐĞĚA? ? ?ǇĞĂƌƐ ?ĐƌĞĂƚŝŶŝŶĞĐůĞĂƌĂŶĐĞ ?ŽĐŬĐƌŽĨƚ ?Gault) gives a more accurate estimate of 
kidney function. 
Aim 
dŽĞǆƉůŽƌĞƚŚĞĞǆƚĞŶƚŽĨƉƌĞƐĐƌŝďŝŶŐŽƵƚƐŝĚĞƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐĨŽƌƉĞŽƉůĞĂŐĞĚA? ? ?ǇĞĂƌƐǁŝƚŚ
reduced kidney function in primary care and to assess the impact of using eGFR instead of creatinine 
clearance to calculate kidney function. 
Design and setting 
A cross-ƐĞĐƚŝŽŶĂůƐƵƌǀĞǇŽĨĂŶŽŶǇŵŝƐĞĚƉƌĞƐĐƌŝďŝŶŐĚĂƚĂŝŶƉĞŽƉůĞĂŐĞĚA? ? ?ǇĞĂƌƐĨƌŽŵĂůů ? ?ŐĞŶĞƌĂů
practices (70 900 patients) in a North of England former primary care trust. 
Method 
The prevalence of prescribing outside recommendations was analysed for eight exemplar drugs. 
Data were collected for age, sex, actual weight, serum creatinine and eGFR. Kidney function as 
creatinine clearance (Cockcroft ?Gault) was calculated using actual body weight and estimated ideal 
body weight. 
Results 
Kidney function was too low for recommended prescribing in 4 ? ? ?A?ŽĨƉĞŽƉůĞĂŐĞĚA? ? ?ǇĞĂƌƐ ?ĂŶĚ
in 24 ? ? ?A?ŽĨƉĞŽƉůĞĂŐĞĚA? ? ?ǇĞĂƌƐ ?ĚĞƐƉŝƚĞŵŽƌĞƚŚĂŶ ? ?A?ŽĨƉĂƚŝĞŶƚƐŚĂǀŝŶŐƌĞĐĞŶƚƌĞĐŽƌĚĞĚ
kidney function results. Using eGFR overestimated kidney function for 3 ? ? ?A?ŽĨƚŚŽƐĞĂŐĞĚA? ? ?
years, and for 13 ? ? ?A?ŽĨƚŚŽƐĞĂŐĞĚA? ? ?ǇĞĂƌƐ ?/ŶĐƌĞĂƐĞĚĂŐĞƉƌĞĚŝĐƚĞĚŚŝŐŚĞƌŽĚĚƐŽĨŚĂǀŝŶŐĂ
kidney function estimate too low for recommended prescribing of the study drugs. 
Conclusion 
Prescribing recommendations when kidney function is reduced are not applied for many people 
ĂŐĞĚA? ? ?ǇĞĂƌƐŝŶƉƌŝŵĂƌǇĐĂƌĞ ?Using eGFR considerably overestimates kidney function for 
prescribing, so creatinine clearance (Cockcroft ?Gault) should be assessed when prescribing for these 
people. Interventions are needed to aid prescribers when kidney function is reduced. 
 
How this fits in 
x Internationally, studies have found that recommendations for prescribing in patients with 
reduced kidney function are often not applied, with increased risk of patient harm and 
hospital admissions. 
x How medicines affected by renal impairment are prescribed to ƚŚŽƐĞĂŐĞĚA? ? ?ǇĞĂƌƐ in UK 
primary care was previously unknown. 
x This survey found many people ĂŐĞĚA? ? ?ǇĞĂƌƐ in UK general practice had a recorded 
estimate of kidney function, but not had drugs adjusted. Data were available to calculate 
creatinine clearance (Cockcroft-Gault); when creatinine clearance estimates were applied 
even more patients were identified as at a risk. 
x The findings from this study have informed an update to the British National Formulary to 
recommend the Cockcroft and Gault formula as the preferred method for estimating renal 
function in elderly patients. 
 
 
Introduction      
Prescribing when ĂƉĂƚŝĞŶƚ ?Ɛkidney function is reduced should include consideration of the risk from 
increased blood levels when drugs excreted renally are eliminated more slowly.1 With ageing, a 
progressive loss of  functional capabilities in most body organs, changed responses to receptor 
stimulation and decreased homeostatic mechanisms, have implications for drug handling. Of these 
changes, excretion is the most significant and important age-related pharmacokinetic change, and is 
both predictable and measurable. Two-thirds of people aged 70-80 years have approximately half 
the kidney function of a  ‘young adult ? 2,3, with an average decline of approximately 1ml/min annually 
after 30yrs old, decreasing more rapidly after 654.  
 
Harm and hospitalisation are potential outcomes when recommendations for altering prescribing 
are not applied. In other European countries, a large primary care study found drug use not 
recommended when kidney function was reduced ŝŶƉĞŽƉůĞĂŐĞĚA? ? ?ǇĞĂƌƐĐĂƵƐĞĚĂ ? ?A?ŝŶĐƌĞĂƐĞ
in all-cause mortality,5 a third of hospital admissions related to adverse drug reactions were judged 
to be due to renal impairment in those aged A? ? ? years6, and one-third of adverse drug reactions in 
people ĂŐĞĚA? ? ?ǇĞĂƌƐduring their hospital stay were associated with reduced kidney function7. 
 
The National Institute for Health and Care Excellence (NICE) guidance on chronic kidney disease 
(CKD)8 ƌĞĐŽŵŵĞŶĚƐ ‘ƌĞǀŝĞǁŽĨŵĞĚŝĐĂƚŝŽŶƐ ? ?ĂŶĚŶŽǁƚŚĞNICE acute kidney injury (AKI) guidelines9 
and alerts are requiring GPs to review medicines after an AKI episode. These include drugs that are a 
direct risk to the kidney, such as non-steroidal anti-inflammatory drugs (NSAIDs), angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs); and drugs that are 
more likely to cause adverse drug reactions when blood levels are increased as a result of slower 
elimination, such as metformin, gabapentin, and pregabalin). Reduced kidney function can also 
reduce the effectiveness of some drugs, such as thiazides and nitrofurantoin.  
 
Estimated Glomerular Filtration Rate (eGFR) has been reported with pathology results since the 
introduction of the CKD guidelines in 2003, and is calculated using ƚŚĞ ‘Modification of Diet in Renal 
Disease ? (MDRD) equation10, and more recently the CKD Epidemiology Collaboration (CKD-EPI) 
formula11. eGFR was developed to provide staging for CKD and does not have a weight component, 
therefore,  making it straight forward for pathology to report. Drug dosing studies, however, have 
used the Cockcroft-Gault equation12 to estimate kidney function ĂƐ ‘Đreatinine ĐůĞĂƌĂŶĐĞ ? (CrCl). 
Cockcroft-Gault includes a weight component: ideal body weight to factor muscle mass, not body 
fat, as creatinine is produced from muscle turnover. 13 The equations give progressively different 
results with increasing age, and studies focussed on prescribing for older people have concluded that 
Cockcroft-Gault should continue to be used for prescribing decisions.14,15 Studies using gentamicin 
have shown that blood levels are more closely estimated by creatinine clearance: while Cockcroft ?
Gault underestimates kidney function and effect on drug blood levels by 10% across all older ages, 
eGFR overestimates kidney function  increasingly as age increases by 29% up to 69%,16 meaning the 
safer estimate to use is Cockcroft-Gault17,18. Use of eGFR for prescribing decisions, rather than 
Cockcroft-Gault, has been shown to lead to more frequent major bleeding events with glycoprotein-
IIb-IIa-inhibitors19, and increases the likelihood of adverse drug reactions20, hospitalisation6, or 
ineffectiveness21.  
 
International studies have found prescribing outside recommendations for older people with 
reduced kidney function 5,22, but, while a similar problem has been shown in a UK hospital 23, to the 
ĂƵƚŚŽƌƐ ? knowledge, no studies have been conducted in UK general practice. The aim of this study 
was to assess whether drugs are prescribed according to the British National Formulary (BNF)13 and 
Electronic Medicines Compendium (eMC), summary of product characteristics 
(www.medicines.org.uk/emc/) when kidney function is reduced, for people aged A?65 years across a 
healthcare population. The study also set out to determine the impact of using eGFR instead of 
creatinine clearance (Cockcroft-Gault) on drug and dosage decisions. 
 
Method 
A cross-sectional survey was conducted on prescribing data from all 80 general practices in a north 
of England former Primary Care Trust (PCT).  
Two drugs, or drug classes, were identified in each of four categories in reduced kidney function: 
x Drugs that should be avoided. 
x Drugs that should have a dose reduction.  
x Drugs that are ineffective. 
x Drugs that require caution as they are known to frequently cause adverse drug reactions in 
renal impairment.  
The eight choices of drugs were based on findings in a previous case-note-review of five practices in 
the PCT24.  Drugs were selected on the strength of the BNF/SPC (summaries of product 
characteristics) recommendations and the literature, 5,21-22,25 ?32, impact on patients,28,33 ?40 and 
independent expert advice from a renal physician, geriatrician, hospital renal pharmacist, and an 
antibiotics expert pharmacist (Table 1). 
Data collection 
Data collection were age, sex, actual weight and date last recorded, serum creatinine and date last 
recorded, eGFR and date last recorded, or no eGFR ever recorded. These data were used to calculate 
creatinine clearance using actual body weight (CrCl-AW) and creatinine clearance using estimated 
ideal body weight (CrCl-IBW). 
Searches were run for all patients prescribed each drug by a PCT data analyst at the end of October 
2011 to extract data from general practice systems. All practices used the TPP SystmOne clinical 
information system. 
Data analysis 
Data quality and missing data analyses were performed, and a descriptive analysis to give: 
x The numbers of ƉĞŽƉůĞĂŐĞĚA? ? ?ǇĞĂƌƐwith eGFR <60 ml/minute/1.73 m2 (NICE CKD level). 
x dŚĞŶƵŵďĞƌƐŽĨƉĞŽƉůĞĂŐĞĚA? ? ? years taking each of the study drugs. 
For each of the eight drugs the number of patients ŝŶĂŐĞďĂŶĚƐA? ? ? ? ? ?-74, 75- ? ? ?ĂŶĚA? ? ?ǇƌƐwere 
assessed; for seven drugs on the repeat medication list, and for nitrofurantoin, at least one 
ƉƌĞƐĐƌŝƉƚŝŽŶŝŶƚŚĞƉƌĞǀŝŽƵƐ ? ?ŵŽŶƚŚƐ ?ĚĞƐĐƌŝďĞĚĂƐ ‘ƉĂƚŝĞŶƚĚƌƵŐĞǀĞŶƚƐ ? ?&ŽƌĞĂĐŚĚƌƵŐ the 
following data were collected and/or calculated: 
x The number of  ?patient drug events ? where a serum creatinine level had been recorded in 
the previous 15 months, and the estimated kidney function was too low for the 
recommended use, calculated using eGFR, CrCl-AW and CrCl-IBW. 
x The number of  ‘patient drug events ? that would be missed if eGFR, or actual weight in 
Cockcroft-Gault, were used. 
x The number of  ‘patient drug events ? for each drug where there was no kidney function 
estimate on the record. 
x Spearman correlation between age and level of kidney function (using SPSS version 21). 
x Logistic regression analysis to explore the effect of ƉĞŽƉůĞĂŐĞĚA? ? ?ǇĞĂƌƐon the likelihood 
of having a kidney function too low for appropriate prescribing of the drug (using SPSS 
version 21). 
Data oversight was provided by the supervisory research team. 
Results 
Thirteen percent of the PCT population were aged A?65 years (70,900/ 549,533), and 1.8% (9,723) 
were aged A?85 years; 26% of those aged A?65 years, and 50% of those aged A?85 years, had a 
documented eGFR <60ml/min/1.73m2.  
A recent kidney function test in the previous 15 months was found on the patient record for 83% of 
patients prescribed NSAIDs, and for 97% prescribed metformin. Only 0.2%-9.7% of the patient drug 
events had no eGFR, and 0%-5.7% did not have the parameters to calculate CrCl-IBW. 
Figure 1 shows the numbers of patients prescribed each of the drugs studied; an ACEI or ARB was 
found to be prescribed for 40% of the 70,900 patients A?65 years.  
Prevalence of kidney function found to be too low for recommended prescribing 
The number of patient drug events where a recent kidney function was available but was too low for 
the recommended drug use ranged from 39.6% (95% CI = 35.8-43.4%) for nitrofurantoin to 3.5% 
(95% CI = 0-11.2% ?ĨŽƌE^/ƐŝŶƚŚŽƐĞĂŐĞĚA? ? ?ǇĞĂƌƐ ?ĂŶĚ ? ? ? ?A? ? ? ?A?/A 75.1-83.9%) 
(nitrofurantoin) to 24.2% (95% CI = 16.4-32.1% ? ?ŵĞƚĨŽƌŵŝŶ ?ĨŽƌƚŚĞƉĂƚŝĞŶƚƐĂŐĞĚA? ? ?ǇĞĂƌƐ ?dĂďůĞ
2). 
Figure 2 shows an example line plot charting the range of kidney function (CrCl-IBW in the previous 
 ? ?ŵŽŶƚŚƐ ?ĨŽƌŶŝƚƌŽĨƵƌĂŶƚŽŝŶĂƚĞĂĐŚĂŐĞůĞǀĞůĨŽƌƚŚŽƐĞĂŐĞĚA? ? ?ǇĞĂƌƐ ? All cases below the line at 
CrCl-IBW 45ml/min had a kidney function likely to be too low for the drug to be effective, and more 
likely to cause adverse drug reactions.28 
Impact of the different equations to estimate kidney function 
Using eGFR to estimate the level of kidney function suggested a much lower number of alterations 
required for drug or dose choice than would be the case using CrCl-IBW (Figure 3). Use of eGFR, 
rather than CrCl-IBW, would mean that the suggested altering or stopping of the study drugs would 
be missed for 3% to 28% of ƚŚŽƐĞĂŐĞĚA? ? ?ǇĞĂƌƐ ?and 13% to 58% for ƚŚŽƐĞĂŐĞĚA? ? ?ǇĞĂƌs. 
Using actual weight in the Cockcroft-Gault equation also found fewer patients that might need 
prescribing alteration, but to a lesser extent than using eGFR: the suggested altering or stopping of 
the study drugs would be missed for 1-10% of ƉĂƚŝĞŶƚƐĂŐĞĚA? ? ?ǇĞĂƌƐ ?. 
Effect of increased age 
Kidney function reduced with age for all groups studied using Spearman correlation, for example, for 
nitrofurantoin [r = -0.608, n = 3,185 p < 0.001]).  
Logistic regression analysis found that, compared to age band 65-74yrs,  ‘patient drug events ? for those 
aged 75-84yrs had higher odds of being prescribed drugs where the kidney function was too low, and 
even higher odds for those A?85 years (Table 3). For example, for nitrofurantoin, using CrCl-IBW the 
patient drug events for people aged 74-84 years had 5.64 (95% CI = 4.58-6.95) times greater odds of 
being prescribed drugs where the kidney function was too low for recommended use, and 29.23 (95% CI 
= 22.75-37.56) times greater odds for those aged A?85 years. 
 
 
Discussion 
Summary 
Prescribing of drugs outside recommendations for use in reduced kidney function was widespread 
for the eight representative drugs in the study population. Using eGFR, rather than CrCl-IBW, 
considerably underestimated potential risk to patients, particularly those aged A? ? ?ǇĞĂƌƐ.  
 Strengths and limitations 
The study population was from a large PCT with a broad range of prescribers. A deprivation score 
higher than the England average, a lower life expectancy, and a slightly younger population40, 
suggests that the study findings might be an under-estimation of the problem in the UK. Only a small 
number of data were excluded, where no kidney function data was available, giving confidence in 
the findings being representative. 
Anonymised  ‘patient drug events ? were collected, but it is likely that many were prescribed more 
than one drug. Inferences cannot be made on the group of drugs as a whole in this study, or the 
prevalence of a patient having more than one drug affected by level of kidney function. A case-note-
review in five GP practices found that 25% of patients aged A? ? ? years were prescribed an average of 
two drugs where the kidney function was too low for recommended use, and 70 different drugs 
were involved24. 
 
Comparison with existing literature 
International prevalence studies in primary and secondary care5,22,25-32, have reported high numbers 
of drug use and dosing outside recommendations. A French multi-centre prospective primary care 
ƐƚƵĚǇĨŽƵŶĚ ? ? ? ?A?ŽĨƉĂƚŝĞŶƚƐA? ? ?ǇĞĂrs with a kidney function too low for recommended use, 
52.5% in those with eGFR 30 ?59, and 96% with eGFR <30 ml/minute/1.73 m2.5 A retrospective case-
record analysis from patients over 70 years in a UK hospital found 13% having  ‘potentially 
inappropriate prescribing ?.23  
 
A recent kidney function level was recorded in the patient record for most (90%) people ĂŐĞĚA? ? ?
years prescribed the included drugs in the current study. The UK Quality Outcomes Framework 
(QOF)48 targets may have helped as kidney function testing has been incentivised, for example in 
diabetes. However, renal impairment did not seem to lead to altered prescribing in all four 
categories of drugs studied, which may impact on patient safety from increased blood levels, 
sensitivity, or ineffectiveness. For all drugs studied, the dose could have been reduced or an 
alternative treatment chosen, such as atorvastatin, which is not affected by level of kidney function, 
instead of simvastatin, or alternative anti-hypertensive or antidiabetic medication. 
 
Increased age predicted higher odds of having a kidney function estimate too low for recommended 
prescribing. This analysis did not address the possibility of confounders, but there is broad evidence 
of progressive loss of kidney function with aging2,3. Those ĂŐĞĚA? ? ?ǇĞĂƌƐare more likely to have a 
lower kidney function, and so a lower reserve to react to assaults such as dehydration or 
nephrotoxicity of drugs. Renal impairment, polypharmacy, and identified drugs such as NSAIDs are 
ŝŶĐůƵĚĞĚĂƐ ‘ĚĞĨŝĐŝƚƐ ?ŝĚĞŶƚŝĨŝĞĚǁŚŝĐŚĐĂŶŽĐĐƵƌǁŝƚŚĂŐŝŶŐĂŶĚĐŽŵďŝŶĞƚŽŝŶĐƌĞĂƐĞ ‘ĨƌĂŝůƚǇ ?ǁŚŝĐŚŝŶ
turn increases the risk of adverse outcomes.44 
 
The equation used to estimate kidney function for prescribing decisions made a substantial 
difference to whether prescribing might be reviewed because of renal impairment in people aged 
A? ? ?ǇĞĂƌƐ. Many other studies report underestimation of kidney function when different equations 
are used, ranging from an Italian hospital study that found 9.8% dosing outside recommendations if 
eGFR was used,50 to a Spanish hospital study of nephrotoxic drugs which found a 65% dosing outside 
recommendations.51 A US primary care study found 40% of patients should have been 
recommended different doses, and 22% of those reviewed would have had different 
recommendations based on the equation chosen.52 The current study found that using eGFR would 
mean that many people needing a review of prescribing would be missed. It also showed that using 
actual weight in the Cockcroft-Gault equation would miss drugs that might need review; an ideal 
body weight, or actual if lower body weight, should be used in the Cockcroft-Gault calculation to give 
an indication of muscle mass.13,14  
 
Implications for practice and research 
Treatment of multi-morbidity has resulted in the increasing numbers of older people being 
prescribed more long term medicines, the mean being seven for people aged A? ? ?ǇĞĂƌƐ ?53 and 60% 
of the billion items dispensed in the community in England are for ƉĞŽƉůĞĂŐĞĚA? ? ?ǇĞĂƌƐ ?54 As many 
older people are prescribed multiple medications, there is the likelihood that people will be taking 
more than one drug eliminated via the kidneys, increasing the complexity of the impact. Applying 
BNF recommendations for prescribing (or avoidance of prescribing) in renal impairment could 
reduce the risk of adverse drug reactions, particularly for the oldest and most frail patient.  
In 2017 the BNF  reviewed this evidence and updated their ƌĞĐŽŵŵĞŶĚĂƚŝŽŶŝŶƚŚĞ ‘WƌĞƐĐƌŝďŝŶŐŝŶ
ZĞŶĂů/ŵƉĂŝƌŵĞŶƚ ?ƐĞĐƚŝŽŶƚŽƐƚĂƚĞƚŚĂƚ  ? ?the Cockcroft and Gault formula is the preferred method 
ĨŽƌĞƐƚŝŵĂƚŝŶŐƌĞŶĂůĨƵŶĐƚŝŽŶŝŶĞůĚĞƌůǇƉĂƚŝĞŶƚƐĂŐĞĚ ? ?෴ǇĞĂƌƐĂŶĚŽǀĞƌ ?13,55. Electronic patient record 
systems, e.g. SystmOne and EMIS, ŚĂǀĞĂ ‘ƌĞŶĂůĐĂůĐƵůĂƚŽƌ ?ƚŽĞŶĂďůĞƉƌĞƐĐƌŝďĞƌƐƚŽĐĂůĐƵůĂƚĞ ? and 
code, creatinine clearance Cockcroft-Gault; smartphone apps are also available and easy to use. 
Pharmacists have been shown to significantly reduce prescribing outside recommendations in 
reduced kidney function56; they can audit, highlight for review, and do medication reviews, for high 
risk populations.  
The data required to calculate creatinine clearance and identify affected drugs are already available 
in the prescribing and consultation systems; it would be possible to develop patient and drug specific 
decision support to suggest safer doses or alternative drugs, both at initiation and at medication 
review. Further research has been undertaken to understand why GPs often do not apply renal 
impairment recommendations when prescribing, and to inform an intervention to aid prescribing in 
reduced kidney function.57 
 
 
Guidelines should consider recommendations for drug use and level of kidney function.58 CKD and 
AKI guidelines could include guidance on prescribing (and avoiding prescribing) to both reduce risk 
to the kidney, and reduce adverse drug reactions from renally excreted drugs. The NHS England 
 ‘dŚŝŶŬ<ŝĚŶĞǇƐ ? ƌĞƐŽƵƌĐĞƐŝŶĐůƵĚĞĂŶ ‘</ŵĞĚŝĐŝŶĞƐŽƉƚŝŵŝƐĂƚŝŽŶƚŽŽůŬŝƚ ? (www.thinkkidneys.nhs.uk) 
aimed at prescribers in hospitals which could be usefully extended to primary care. Non-prescription 
medicines could be important for future research, for example NSAIDs bought from pharmacies or 
retail outlets.  
 
 
Conclusion 
Prescribing recommendations in reduced kidney function were not applied for a large number of 
people ĂŐĞĚA? ? ?ǇĞĂƌƐ, in this first UK general practice study. Assessment of Cockcroft-Gault 
creatinine clearance to estimate kidney function level when making prescribing decisions for people 
ĂŐĞĚA? ? ?ǇĞĂƌƐwill find more at risk of higher drug blood levels than eGFR, and reduce the risk of 
harm. 
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 Abbreviations: ACEIs  ? angiotensin-converting enzyme inhibitors; ARBs  ? angiotensin II receptor blockers; CrCl  ? creatinine clearance; NSAIDs  ? non-
steroidal anti-inflammatories.  
Table 1: Choices of drugs and drug classes to investigate in the survey    
category: 
recommendation 
when kidney 
function is reduced
drug BNF13/ SPC recommendation
%  prescribing 
outside 
recommendations, 
or dose suggested 
may need review, in 
a case-note review 
study24
references where prescribing 
outside recommendations was 
reported 
evidence of potential impact for patients
comments from indendent experts in the 
field (a renal physician with a national role, 
geriatrician, hospital renal pharmacist, and 
an antibiotics expert pharmacist)
alendronic acid SPC - 'not recommended'BNF: 'avoid if CrCl<35ml/min' 4.0
Breton et al (2011)5
Khanal et al,(2015)22
$OHQGURQLFDFLGDFFXPXODWHVLQWKHERQHVZLWKDWHUPLQDOKDOIOLIHRIRYHUWHQ\HDUV
0+5$UHYLHZRIULVNVDVVRFLDWHGZLWKDQLQFUHDVHGULVNRIDW\SLFDOVWUHVVIUDFWXUHVRI
  the proximal femoral shaft; low but increased risk of atrial fibrillation.33
Agreed to be included.
metformin
SPC: 'contra-indication < 30 
mL/min' 2.0
Breton et al (2011)5
Khanal et al (2015)22
Schmidt-Mende et al (2012)25
,QFUHDVHGULVNRIODFWLFDFLGRVLVHVSHFLDOO\ZLWKGHK\GUDWLRQ34
Suggested by a renal physician and a 
geriatrician as they see admissions to 
hospital caused by metformin when 
kidney function is low.
simvastatin
SPC/BNF: 'CrCl < 30 ml/min: 
dosages above 10 mg/day should 
be carefully considered and, if 
deemed necessary, implemented 
cautiously.'
8.8 Breton et al (2011)5 
7RWDOGUXJ$8&WLPHVJUHDWHUZKHQNLGQH\IXQFWLRQLVORZ3HUVRQDOFRPPXQLFDWLRQ
   by S Wood to Merck Sharp & Dohme, 12 October 2011) (ie greater than the effect of the
   drug interaction with amoldipine: AUC for simvastatin increased by 1.58-1.77 fold35)
0+5$
LQFUHDVHGSODVPDFRQFHQWUDWLRQVRIVLPYDVWDWLQDUHDVVRFLDWHGZLWKDQLQFUHDVHG
  risk of myopathy and/or rhabdomyolysis.35
Agreed to be included as a widely used 
drug with an alternative availbale 
(atorvastatin does not need dose 
alteration when kidney function is low42).
gabapentin and 
pregabalin
table of reduced doses at specified 
levels of CrCl 0.2 Breton et al (2011)
5
+LJKULVNIURPWKHFRPPRQDGYHUVHHIIHFWVRIVRPQROHQFHGL]]LQHVVDWD[LDDQG
  fatigue.43.44
7KHUHKDVEHHQDULVHLQSUHVFULELQJRIJDEDSHQWLQDQGULVHLQSUHJDEDOLQ
  prescribing since 2011.36
Added at the suggestion of the renal 
pharmacist because of frequent side 
effects seen in the renal unit.
thiazides BNF: 'likely to be ineffective at CrCl<30ml/min' 17.0 Howard et al (2003)
26 8QOLNHO\WREHHIIHFWLYHEHORZPOPLQ45
,QFUHDVHGULVNRIDGYHUVHHYHQWVVXFKDVHOHFWURO\WHLPEDODQFH25 Agreed to be included.
nitrofurantoin
BNF: 'likely to be ineffective at 
CrCl<45ml/min'
SPC: contraindicated <45ml/min; 
may be used with caution 30-
44ml/min - only prescribe to such 
patients to treat lower urinary tract 
infection with suspected or proven 
multidrug resistant pathogens when 
the benefits of nitrofurantoin are 
considered to outweigh the risks of 
side effects.
0.2 (on repeat)
Farag et al (2014)27
Geerts et al (2013)28
Howard and Wood (2013)21
0+5$
7KHDQWLEDFWHULDOHIILFDF\GHSHQGVRQWKHUHQDOVHFUHWLRQRIQLWURIXUDQWRLQLQWRWKH
  urinary tract. In patients with renal impairment, renal secretion of nitrofurantoin is reduced. 
  This may reduce the antibacterial efficacy, increase the risk of side effects (eg, nausea, 
  vomiting, loss of appetite), and may result in treatment failures.37
7KHGUXJPD\QRWZRUNLQFUHDVLQJULVNIURPLQIHFWLRQ46 An audit in a large GP practice  
  found older people with renal  impairment were more likely to need further antibiotics21
5DLVHGEORRGOHYHOVLQFUHDVHVWKHULVNRISXOPRQDU\KHSDWLFQHXURORJLFDOKDHPDWRORJLFDO
  and gastrointestinal side effects during treatment.; <50 ml/min significanlty increased the 
  risk of pulmonary adverse events leading to hospitalisation (HR 4.1, CI 1.39-13.09)28 
Agreed to be included; issue raised after 
discussion with a pharmacist with 
international expertise in antibiotics.
NSAIDs
BNF: 'caution in reduced kidney 
function' (study parameter set at 
<30ml/min)
1.7
Evans et al (1995)29
Guthrie et al (2011)30 
Howard et al (2003)26 
Ingrasciotta et al (2014)31 
6RGLXPDQGZDWHUUHWHQWLRQPD\RFFXUDQGUHQDOIXQFWLRQPD\GHWHULRUDWHSRVVLEO\
  leading to renal failure; deterioration in renal function has also been reported after topical 
  use.13
&KURQLFXVHRI16$,'VLVDULVNIDFWRUIRUSURJUHVVLRQRI&.'8 
)UHTXHQWO\FLWHGDVFDXVLQJDGPLVVLRQV.38
Agreed to be included: NSAIDs affect all 
stages of kidney function and are 
frequently a cause of hospital admission.
ACEIs and ARBs
BNF: 'caution in  reduced kidney 
function' (study parameter set at 
<30ml/min)
26.0
Breton et al (2011)5
Handler et al (2014)32
Khanal et al (2015)22 
Schmidt-Mende et al (2012)25
5DPLSULO63&&U&OPOPLQPD[LPXPGRVHLVPJ47
+\SHUNDODHPLDDQGRWKHUVLGHHIIHFWVRI$&(LQKLELWRUVDUHPRUHFRPPRQDQGWKHGRVH
  may need to be reduced.13
&DQFDXVHLPSDLUPHQWRINLGQH\IXQFWLRQZKLFKPD\SURJUHVVDQGEHFRPHVHYHUHDW
  particular risk are the elderly).13

6723$&(
VWXG\LVLQYHVWLJDWLQJZKHWKHUWKHULVNWRWKHNLGQH\PD\RXWZHLJKDQ\
  beneficial effect if <30 ml/min.39 
Although ACEIs and ARBs are used in 
renal disease, they can also be 
nephrotoxic so the consultant experts 
suggested inclusion.
caution as ADRs 
are likely
avoid
reduce the dose
ineffective
  
 
 
 
Figure 1:  Number of pĞŽƉůĞĂŐĞĚA? ? ?ǇĞĂƌƐŝŶƚŚĞPCT prescribed each of the study drugs 
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alendronic acid (n = 4,230)
  
 
Table 2: EƵŵďĞƌŽĨĚƌƵŐƐƉƌĞƐĐƌŝďĞĚĨŽƌƉĞŽƉůĞĂŐĞĚA? ? ?ǇĞĂƌƐǁŝƚŚĂŬŝĚŶĞǇĨƵŶĐƚŝŽŶĞƐƚŝŵĂƚĞ ?ƌů-CG IBW) in the previous 15 months below that for 
recommended use. 
Patients with no eGFR on the record, or kidney function data older than 15 months, were excluded for the final analysis (9911/96 900 (10.2%). 
 
 
total
kidney 
function 
< 
recmd'd
% 95% CI total
kidney 
function 
< 
recmd'd
% 95% CI total
kidney 
function 
< 
recmd'd
% 95% CI total
kidney 
function 
< 
recmd'd
% 95% CI
alendronic acid 3,400 804 23.6 (19.2-28.1) 1,120 49 4.4 (3.6-5.1) 1,532 342 22.3 (20.1-24.6) 748 413 55.2 (48.6-61.8)
metformin 6,276 267 4.3 (1.2-7.3) 3,491 30 0.9 (0.81-0.91) 2,319 124 5.3 (4.9-5.8) 466 113 24.2 (16.4-32.1)
simvastatin > 10mg 19,434 1,465 7.5 (6.6-8.5) 9,894 167 1.7 1.65-1.72 7,494 643 8.6 (8.4-8.8) 2,046 655 32.0 (29.9-34.1)
gabapentin or pregabalin 1,209 132 10.9 (0-25.7) 598 43 7.2 (5.0-9.4) 450 56 12.4 (7.6-17.3) 161 33 20.5 (0.3-40.7)
nitrofurantoin 3,185 1,262 39.6 (35.8-43.4) 1,206 141 11.7 (10.0-13.4) 1,242 535 43.1 (39.1-47.0) 737 586 79.5 (75.1-83.9)
thiazide 10,805 797 7.4 (5.7-9.1) 5,371 62 1.2 (1.11-1.20) 4,189 303 7.2 (6.9-7.6) 1,245 432 34.7 (31.1-38.3)
NSAID 2,483 86 3.5 (0-11.2) 1,577 8 0.5 (0.44-0.57) 762 36 4.7 (3.5-5.9) 144 42 29.2 (0.5-57.9)
ACE/ARB 26,109 2,521 9.7 (9.0-10.3) 12,663 288 2.3 (2.24-2.31) 10,280 1,062 10.3 (10.2-10.5) 3,166 1,171 37.0 (35.5-38.5)
aged 85yrs and older
drug
aged 65yrs and older aged 65-74yrs aged 75-84yrs
 Figure 2: Line plot charting the range of kidney function using creatinine clearance Cockcroft-
Gault(CrCl-IBW) within the previous 15 months, for nitrofurantoin prescribed for people at each age 
level 65 years and older. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3: A chart of the percentage of patients found with a kidney function too low for 
recommended use of the drug using eGFR compared to creatinine clearance (CrCl) Cockcroft-Gault in 
the 3 older age bands.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3: The odds of having a kidney function too low for the drug with increased age compared to those 
aged 65-74 years, using eGFR, creatinine clearance calculated using actual weight (CrCl-AW), and ideal 
body weight (CrCl-IBW)  
 
 
 
 
65-74yrs
eGFR 1 1.96 (1.08-3.56) 5.49 (3.07-9.81)
CrCl-CG AW 1 5.11 (3.59-7.26) 24.12 (16.93-34.36)
CrCl-CG IBW 1 6.28 (4.61-8.57) 26.95 (19.56-37.13)
eGFR 1 2.26 (0.80-6.35) 6.15 (1.87-6.35)
CrCl-CG AW 1 5.90 (3.20-10.88) 48.64 (26.70-88.61)
CrCl-CG IBW 1 6.52 (4.36-9.75) 36.93 (24.33-58.05)
eGFR 1 2.45 (1.89-3.17) 4.98 (3.71-6.70)
CrCl-CG AW 1 5.03 (4.06-6.23) 30.64 (24.73-37.95)
CrCl-CG IBW 1 5.47 (4.60-6.50) 27.43 (22.93-32.80)
eGFR 1 2.19 (1.42-3.37) 5.29 (3.32-8.43)
CrCl-CG AW 1 5.60 (3.96-7.93) 49.67 (35.52-69.44)
CrCl-CG IBW 1 6.68 (5.07-8.80) 45.50 (34.52-59.98)
eGFR 1 4.20 (1.05-16.84) 3.68 (0.38-35.57)
CrCl-CG AW 1 3.50 (1.52-8.03) 43.93 (20.31-95.03)
CrCl-CG IBW 1 9.73 (4.50-21.03) 80.76 (36.94-176.55)
eGFR 1 1.81 (1.49-2.21) 3.84 (3.09-4.78)
CrCl-CG AW 1 4.73 (3.98-5.61) 29.01 (24.27-34.38)
CrCl-CG IBW 1 4.95 (4.33-5.65) 25.22 (21.99-28.93)
eGFR 1 2.73 (1.27-5.89) 4.28 (1.78-10.26)
CrCl-CG AW 1 2.97 (1.55-5.72) 9.96 (5.25-18.88)
CrCl-CG IBW 1 1.83 (1.21-2.79) 3.33 (2.03-5.45)
eGFR 1 3.03 (4.20-4.18) 5.24 (3.78-7.27)
CrCl-CG AW 1 6.79 (5.16-8.92) 41.33 (30.87-55.36)
CrCl-CG IBW 1 5.64 (4.58-6.95) 29.23 (22.75-37.56)
75-84yrs 85 years and older
odds ratio odds ratio
alendronic acid 
metformin
simvastatin >10mg
thiazides
nitrofurantoin
NSAIDs
ACE/ARBs
Gabapentin/pregabalin
